Page last updated: 2024-12-09

1-(6-methyl-2-pyridinyl)-3-(2-phenylethyl)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a specific chemical compound: **1-(6-methyl-2-pyridinyl)-3-(2-phenylethyl)thiourea**.

**Understanding the Compound:**

* **Structure:** This compound is a thiourea derivative. Thioureas are organic compounds containing a carbon atom double-bonded to a sulfur atom and single-bonded to two nitrogen atoms.
* **Substituents:** The compound has two key substituents:
* **6-methyl-2-pyridinyl:** This is a pyridyl ring (a six-membered nitrogen-containing ring) with a methyl group at the 6th position and a nitrogen atom at the 2nd position.
* **2-phenylethyl:** This is a phenyl group (a benzene ring) attached to an ethyl group (two carbon chain).
* **Overall Structure:** The thiourea group connects the pyridinyl and phenylethyl substituents.

**Why it Might be Important for Research:**

You're right to ask why this compound is important. It's unlikely to be a well-known, widely studied compound. Here's why:

* **Potential Applications:**
* **Pharmacology:** Thioureas are known to have a variety of biological activities, including anti-inflammatory, anti-cancer, and antimicrobial properties. This specific compound, with its unique structure, might exhibit interesting pharmacological effects.
* **Materials Science:** Thioureas can act as building blocks for polymers and other materials, and the specific substituents might influence their properties.
* **Novelty:** Given its unique structure, it's possible this compound hasn't been studied extensively before.
* **Synthetic Challenge:** The synthesis of thiourea derivatives can be challenging, and this specific compound might be a target for synthetic chemists.

**To find out more about this compound, you would need to:**

* **Search scientific databases:** Use databases like SciFinder, PubMed, and Reaxys to see if any research has been done on this specific compound or similar thiourea derivatives.
* **Contact researchers:** Reach out to experts in the fields of organic chemistry, medicinal chemistry, or materials science to inquire about their knowledge or ongoing research related to this type of compound.

**Remember:** The importance of a chemical compound is often determined by the specific research question being investigated. Without more context about the research goals, it's difficult to say definitively why this specific compound is important.

Cross-References

ID SourceID
PubMed CID1952370
CHEMBL ID1331816
CHEBI ID108968

Synonyms (13)

Synonym
smr000294842
MLS000664897
n-(6-methyl-2-pyridinyl)-n'-(2-phenylethyl)thiourea
1-(6-methylpyridin-2-yl)-3-(2-phenylethyl)thiourea
STK164818
CHEBI:108968
AKOS001094219
HMS2696I16
CHEMBL1331816
Q27187945
1-(6-methyl-2-pyridinyl)-3-(2-phenylethyl)thiourea
SR-01000281317-1
sr-01000281317
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylpyridinesAny member of the class of pyridines that carries at least one methyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.81140.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency37.93300.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency7.07950.01846.806014.1254AID624417
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency32.62940.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency24.50140.000811.382244.6684AID686978; AID686979
thioredoxin glutathione reductaseSchistosoma mansoniPotency28.18380.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
67.9K proteinVaccinia virusPotency11.22020.00018.4406100.0000AID720579
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency33.58750.168316.404067.0158AID720504
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency56.23410.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency1.86230.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency14.58100.004611.374133.4983AID624297
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency6.30960.025911.239831.6228AID602313
lamin isoform A-delta10Homo sapiens (human)Potency19.95260.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]